Pfizer has co-developed an anti-PD L1 cancer drug Bavencio (avelumab) with Merck, which has now been granted approval to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma from European regulators.
from Forbes Real Time https://www.forbes.com/sites/greatspeculations/2017/09/27/bavencios-eu-nod-a-positive-for-pfizers-oncology-business/
via IFTTT
No comments:
Post a Comment